David Macdonald

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.

Gregory Cairncross, David Macdonald, Samuel K. Ludwin et al. · Journal of Clinical Oncology · 1994 · 442 citations

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

James Perry, Karl Bélanger, Warren Mason et al. · Journal of Clinical Oncology · 2010 · 380 citations

Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation.

C. Leighton, B. Fisher, Glenn Bauman et al. · Journal of Clinical Oncology · 1997 · 369 citations

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

M. Brada, Khê Hoang‐Xuan, R. Rampling et al. · Annals of Oncology · 2001 · 369 citations · Full text

Neuro-oncology, Glioma, Glioblastoma Multiforme +8